Overview

The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases

Status:
RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The goal of this monocentric double blinded cross over trial is to evaluate safety and tolerability of inhaled furosemide in patients with pulmonary diseases and dyspnea. The main question\[s\] it aims to answer are: * is inhaled furosemide safe and well tolerated? * is inhaled furosemide capable of dyspnea suppression and is there any additive effect of levodropropizine Participants will be given: * inhaled furosemide or placebo in double blinded cross over manner. Dyspnea severity and vital functions will be measured, adverse reactions monitored * all participants will receive levodropropizine open label. Dyspnea severity and vital functions will be measured, adverse reactions monitored

Phase:

PHASE2

Details

Lead Sponsor:

University Hospital Hradec Kralove

Collaborator:

Masaryk University

Treatments:

dipropizine
Furosemide